Long-Term Gender-Affirming Hormone Therapy and Cognitive Functioning in Older Transgender Women Compared With Cisgender Women and Men

被引:9
|
作者
van Heesewijk, Jason O. [1 ,2 ]
Dreijerink, Koen M. A. [1 ,2 ]
Wiepjes, Chantal M. [1 ,2 ]
Kok, Almar A. L. [3 ]
van Schoor, Natasja M. [3 ]
Huisman, Martijn [3 ]
den Heijer, Martin [1 ,2 ]
Kreukels, Baudewijntje P. C. [4 ]
机构
[1] Amsterdam Univ Med Ctr, Dept Endocrinol, Locat VUmc, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam Univ Med Ctr, Ctr Expertise Gender Dysphoria, Locat VUmc, Amsterdam, Netherlands
[3] Amsterdam Univ Med Ctr, Dept Epidemiol & Data Sci, Locat VUmc, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Dept Med Psychol, Locat VUmc, Amsterdam, Netherlands
来源
JOURNAL OF SEXUAL MEDICINE | 2021年 / 18卷 / 08期
关键词
Gender Dysphoria; Older Transgender Women; Gender-Affirming Hormone Therapy; Cognitive Functioning; Cardiovascular Risk; Psychological Functioning; BREAST-CANCER; ENDOCRINE TREATMENT; HEALTH; RISK; ESTRADIOL; PEOPLE; AGE;
D O I
10.1016/j.jsxm.2021.05.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Long-term gender-affirming hormone therapy (GHT) in older transgender individuals could have beneficial effects on cognitive functioning. Cardiovascular risk factors and psychological factors are known determinants of cognition. Despite the rising number of older transgender individuals, only few studies have examined cognitive functioning in this population. Aim: We aimed to assess differences in cognitive functioning between transgender women, and non-transgender (cisgender) women and men, and investigated the contribution of cardiovascular risk factors and psychological factors on these differences. Methods: In this study, 37 transgender women (age range 55 to 69) receiving GHT for at least ten years (range 10.2 to 41.6) were examined, and their cognitive functioning was compared to an age and education level matched cohort consisting of 222 cisgender women and men from the Longitudinal Aging Study Amsterdam. Linear regression analyses were performed. Outcomes: Cognitive functioning was assessed by neuropsychological tests including Mini-Mental State Examination (MMSE), Category Fluency animals, Letter Fluency D, 15-Word test (15WT) immediate and delayed recall. Additionally, cardiovascular risk factors and psychological factors such as cardiovascular disease, hypertension, antihypertensive use, statin use, diabetes mellitus, overweight, smoking, alcohol consumption, psychophar-maceutical use, anxiety and depression symptoms were collected. Results: Transgender women had higher MMSE scores compared with cisgender women (+0.9, 95% CI 0.4 to 1.5), and cisgender men (+1.1, 95% CI 0.4 to 1.8). On all other tests transgender women performed similar to cisgender men. Transgender women performed at a lower level than cisgender women on 15WT immediate recall,-5.5, 95% CI-7.6 to -3.4, and 15WT delayed recall,-2.7, 95% CI-3.7 to-1.7, and equal to cisgender women on Fluency animals and Fluency D. Cardiovascular and psychological factors (i.e., cardiovascular disease and depression symptoms) partly explained differences on MMSE score between transgender women and cisgen-der-control groups. Clinical Implications: The results of this study do not indicate a need for tailored hormone treatment strategies for older transgender women, based on cognitive aspects after long-term GHT. Strengths & Limitations: As one of the first studies, this study compared older transgender women to a large cohort of cisgender men and women regarding cognitive functioning and took into account numerous potential influencing factors. Limitations include difference in test procedures and the cross-sectional design of the study. Conclusion: Cognitive differences between transgender women and cisgender women and men were small, albeit significant. This may suggest that long-term GHT effects on cognitive functioning in older transgender women are minimal. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
引用
收藏
页码:1434 / 1443
页数:10
相关论文
共 50 条
  • [31] A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people
    David Matthew Doyle
    Tom O. G. Lewis
    Manuela Barreto
    Nature Human Behaviour, 2023, 7 : 1320 - 1331
  • [32] Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons Comment
    Tangpricha, Vin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (06): : E2632 - E2633
  • [33] Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy
    Mullins, Eric S.
    Geer, Rebecca
    Metcalf, Megan
    Piccola, Jeanne
    Lane, Adam
    Conard, Lee Ann E.
    Mullins, Tanya L. Kowalczyk
    PEDIATRICS, 2021, 147 (04)
  • [34] Blood pressure changes with gender-affirming hormone therapy in transgender people
    Michihiro Satoh
    Hypertension Research, 2023, 46 : 792 - 793
  • [35] Blood pressure changes with gender-affirming hormone therapy in transgender people
    Satoh, Michihiro
    HYPERTENSION RESEARCH, 2023, 46 (03) : 792 - 793
  • [36] The Effect of Gender-Affirming Hormone Therapy on Serum Creatinine in Transgender Individuals
    Maheshwari, Arvind
    Dines, Virginia
    Saul, Dominik
    Nippoldt, Todd
    Kattah, Andrea
    Davidge-Pitts, Caroline
    ENDOCRINE PRACTICE, 2022, 28 (01) : 52 - 57
  • [37] A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people
    Doyle, David Matthew
    Lewis, Tom O. G.
    Barreto, Manuela
    NATURE HUMAN BEHAVIOUR, 2023, 7 (08) : 1320 - 1331
  • [38] Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people
    Santi, D.
    Spaggiari, G.
    Marinelli, L.
    Cacciani, M.
    Scipio, S.
    Bichiri, A.
    Profeta, A.
    Granata, A. R. M.
    Simoni, M.
    Lanfranco, F.
    Manieri, C.
    Ghigo, E.
    Motta, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (05) : 1091 - 1100
  • [39] Metabolic consequences of gender-affirming hormone therapy in transgender adult persons
    Vloemans, Nadia
    Al-Mrayat, Ma'en
    PRACTICAL DIABETES, 2023, 40 (03) : 12 - 15
  • [40] Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people
    D. Santi
    G. Spaggiari
    L. Marinelli
    M. Cacciani
    S. Scipio
    A. Bichiri
    A. Profeta
    A. R. M. Granata
    M. Simoni
    F. Lanfranco
    C. Manieri
    E. Ghigo
    G. Motta
    Journal of Endocrinological Investigation, 2024, 47 : 1091 - 1100